Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Liabilities (2019 - 2025)

Allogene Therapeutics' Other Non-Current Liabilities history spans 7 years, with the latest figure at $15.5 million for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 101.87% year-over-year to $15.5 million; the TTM value through Sep 2025 reached $15.5 million, up 101.87%, while the annual FY2024 figure was $7.8 million, 49.86% up from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $15.5 million at Allogene Therapeutics, up from $15.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $15.5 million in Q3 2025 and bottomed at $1.5 million in Q3 2023.
  • The 5-year median for Other Non-Current Liabilities is $5.2 million (2021), against an average of $5.9 million.
  • The largest annual shift saw Other Non-Current Liabilities tumbled 60.71% in 2022 before it surged 415.88% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $4.1 million in 2021, then soared by 41.75% to $5.8 million in 2022, then dropped by 11.42% to $5.2 million in 2023, then skyrocketed by 49.86% to $7.8 million in 2024, then soared by 99.39% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Other Non-Current Liabilities are $15.5 million (Q3 2025), $15.1 million (Q2 2025), and $11.3 million (Q1 2025).